Requests For EMA PRIME Designation Fall But Improvements Are On The Way

 
• By Neena Brizmohun

While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.

The PRIME scheme can help drug developers understand how to generate robust data • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards